Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash & Equivalents (2023 - 2025)

Kura Oncology (KURA) has disclosed Cash & Equivalents for 3 consecutive years, with $149.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 33.57% to $149.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.1 million, a 33.57% decrease, with the full-year FY2025 number at $149.1 million, down 33.57% from a year prior.
  • Cash & Equivalents was $149.1 million for Q4 2025 at Kura Oncology, up from $95.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $224.5 million in Q4 2024 to a low of $27.1 million in Q1 2023.
  • A 3-year average of $73.4 million and a median of $49.3 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 501.48% in 2024, then plummeted 33.57% in 2025.
  • Kura Oncology's Cash & Equivalents stood at $37.3 million in 2023, then surged by 501.48% to $224.5 million in 2024, then tumbled by 33.57% to $149.1 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Cash & Equivalents are $149.1 million (Q4 2025), $95.3 million (Q3 2025), and $81.9 million (Q2 2025).